Regis Technologies has reported the successful outcome of its routine U.S. FDA inspection, which found no objectionable findings, meaning no Form 483 observations were issued. This marks the fourth consecutive inspection for Regis without incident.   The inspection was a routine Quality Systems inspection to support Regis’ FDA registration and ongoing manufacture of clinical and commercial active pharmaceutical ingredients (APIs). The four-day, onsite inspection resulted in an NAI (No Action Ind...